| 1 |
35083346 | Impact of 18F-FDG PET/CT on treatment of patients with differentiated thyroid carcinoma, negative 131I whole body scan and elevated serum thyroglobulin. | 2022 Winter |
5 |
| 2 |
35256297 | Positron Emission Tomography/Computed Tomography in Thyroid Cancer. | 2022 Apr |
1 |
| 3 |
35521710 | FDG PET/CT in differentiated thyroid cancer patients with low thyroglobulin levels. | 2022 May 24 |
1 |
| 4 |
32379488 | Role of Thyroglobulin Doubling Time in Differentiated Thyroid Cancer and Its Relationship with Demographic-Histopathologic Risk Factors and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Parameters. | 2021 Jun |
3 |
| 5 |
33824601 | Value of 18F-FDG Hybrid PET/MR in Differentiated Thyroid Cancer Patients with Negative 131I Whole-Body Scan and Elevated Thyroglobulin Levels. | 2021 |
2 |
| 6 |
33926848 | PET/CT in the management of differentiated thyroid cancer. | 2021 Sep |
1 |
| 7 |
34014437 | The role of Tg kinetics in predicting 2-[18F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan. | 2021 Nov |
1 |
| 8 |
34066574 | A Stepwise Approach Using Metastatic Lymph Node Ratio-Combined Thyroglobulin for Customization of [18F]FDG-PET/CT Indication to Detect Persistent Disease in Patients with Papillary Thyroid Cancer. | 2021 May 6 |
1 |
| 9 |
32601803 | Comparison of simultaneous 18F-2-[18F] FDG PET/MR and PET/CT in the follow-up of patients with differentiated thyroid cancer. | 2020 Dec |
1 |
| 10 |
32935188 | 18F-FDG-PET/CT indication in patients affected by differentiated thyroid cancer with elevated serum thyroglobulin and negative whole-body scanning after therapy with 131I. | 2020 Dec |
1 |
| 11 |
33025094 | Response to the letter to the editor "18F-FDG-PET/CT indication in patients affected by differentiated thyroid cancer with elevated serum thyroglobulin and negative whole-body scanning after therapy with 131I". | 2020 Dec |
1 |
| 12 |
33082675 | The Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Differentiated Thyroid Cancer Patients with Biochemical Recurrence and Negative Whole-Body Radioiodine Scintigraphy and Evaluation of the Possible Role of a Limited Regional Scan. | 2020 Jul-Sep |
2 |
| 13 |
29130586 | Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer. | 2018 Jan |
1 |
| 14 |
28585147 | Optimal threshold of stimulated serum thyroglobulin level for 18F-FDG PET/CT imaging in patients with thyroid cancer. | 2017 Jun |
2 |
| 15 |
27383190 | The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan. | 2016 Sep |
1 |
| 16 |
25679071 | Is it practical and cost effective to detect differentiated thyroid carcinoma metastases by (18)F-FDG PET/CT, by (18)F-FDG SPET/CT or by (131)I SPET/CT? | 2015 Jan-Apr |
1 |
| 17 |
25720709 | F-18 FDG PET/CT imaging in the diagnostic work-up of thyroid cancer patients with high serum thyroglobulin, negative I-131 whole body scan and suppressed thyrotropin: 8-year experience. | 2015 |
1 |
| 18 |
25246834 | Clinical determinants of fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)iodine whole body scans after (131)iodine therapy. | 2014 May |
1 |
| 19 |
21850699 | Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. | 2012 May |
2 |
| 20 |
21113746 | Role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative ¹³¹I scan: review of the literature. | 2010 Nov |
1 |
| 21 |
21712915 | New Intraspinal cause of physiological FDG uptake. | 2010 Oct |
2 |
| 22 |
19415387 | Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer. | 2009 Jul |
2 |
| 23 |
17538522 | Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. | 2008 Mar |
2 |
| 24 |
17103166 | Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? | 2007 Apr |
2 |
| 25 |
17560521 | Contemporary imaging for thyroid cancer. | 2007 Apr |
1 |
| 26 |
15701340 | [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan]. | 2005 Jan-Feb |
1 |
| 27 |
15902358 | Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans. | 2005 Jun |
3 |
| 28 |
12856803 | F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan. | 2003 May |
3 |
| 29 |
10404792 | [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. | 1999 Jul |
2 |
| 30 |
8790195 | Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. | 1996 Sep |
1 |